查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971453

Echinocandins B 市場 - 全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、地區和競爭格局分類，2021-2031 年

Echinocandin B Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Powder, Liquid), By Application (Antifungal Drugs, Drug Development, Others), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球EchinocandinsB市場預計將從2025年的475.8億美元成長到2031年的657.5億美元，複合年成長率達到5.54%。

EchinocandinsB是一種關鍵的脂肽中間體，通常透過麴菌屬真菌發酵獲得，是合成Echinocandins類抗真菌藥物（如阿尼芬淨）的必需原料。此市場成長的主要驅動力是全球侵襲性真菌感染疾病發生率的上升，以及免疫力缺乏患者對Azole抗藥性病原體有效治療的需求。日益加重的疾病負擔也支持了這項需求。根據全球預防真菌感染疾病基金（GAFF）2024年的預測，全球每年約有655萬人受到危及生命的真菌疾病的影響，這直接催生了對這些重要藥物前體的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 475.8億美元
市場規模：2031年 657.5億美元
複合年成長率：2026-2031年 5.54%
成長最快的細分市場 藥物研發
最大的市場 北美洲

儘管市場需求強勁，但由於Echinocandins類藥物的治療成本高於傳統的Azole藥物，因此面臨巨大的市場障礙。EchinocandinsB核的生產需要複雜的發酵和半合成工藝，這導致生產成本增加，最終必然反映在最終價格上。這種經濟障礙阻礙了這些療法在醫療預算有限且對價格敏感的發展中地區的廣泛應用，從而限制了市場擴張的整體潛力。

市場促進因素

多重抗藥性真菌病原體的日益增加是推動全球EchinocandinsB市場擴張的主要因素。隨著器官移植和腫瘤治療的增加，免疫力缺乏患者的數量不斷成長，導致他們更容易感染嚴重的真菌，因此需要建立健全的棘Echinocandins中間體供應鏈。耳Auris等病原體的快速傳播凸顯了這種緊迫性，這些病原體通常對傳統的Azole藥物具有抗藥性，使得Echinocandins類藥物成為首選的第一線治療方案。根據美國疾病管制與預防中心（CDC）於2024年12月發布的《追蹤耳念珠菌》監測報告，2023年美國該多重抗藥性真菌的臨床病例數達到4514例，顯示這一趨勢仍在持續，直接推高了對高效脂肽類抗真菌藥物的需求。

同時，新型抗真菌藥物製劑的研發擴張推動了對高純度EchinocandinsB核的需求，並重塑了市場動態。製藥公司正積極推動下一代Echinocandins的商業化，這些藥物具有更高的穩定性和更靈活的給藥方案，而這一過程高度依賴先進的半合成生產技術。 2024年5月，Sidala Therapeutics在其2024年第一季財報中宣布，其新型Echinocandins藥物rezafungin已接受歐盟核准，並從Mundipharma公司獲得約1110萬美元的里程碑付款，證實了這些先進治療方法的商業性可行性。為了進一步體現對此治療領域的信心，F2G在2024年獲得了由AMR行動基金主導的1億美元資金籌措，用於推進後期抗真菌藥物的研發。這凸顯了全球投資湧入該領域的重要性。

市場挑戰

Echinocandins類藥物的高昂價格嚴重阻礙了其市場擴張，尤其是在對成本高度敏感的發展中地區。EchinocandinsB核的生產涉及複雜的發酵和半合成工藝，這本身就增加了生產成本。這些高成本最終會轉嫁到藥品價格上，這對預算有限的醫療系統造成了巨大的經濟負擔。因此，儘管Echinocandins藥物具有顯著的臨床療效，但這些地區的醫療服務提供者不得不依賴傳統的低成本Azole藥物，這限制了這些先進療法的潛在市場。

真菌感染疾病對醫療基礎設施帶來的廣泛經濟負擔進一步加劇了價格敏感性，迫使管理者嚴格控制藥品成本。根據美國感染疾病學會估計，到2024年，真菌感染疾病對美國造成的年度經濟負擔總額約為194億美元。如此巨大的經濟壓力迫使醫療機構優先考慮成本控制，導致他們傾向於選擇更經濟實惠的替代療法，進一步抑制了高階Echinocandins類藥物的使用率，直接阻礙了全球EchinocandinsB市場規模的成長。

市場趨勢

新一代長效衍生物的出現從根本上改變了Echinocandins中間體的商業性格局，將市場從每日給藥方案（如阿尼芬淨）轉向每週一次的給藥方案。這種轉變要求EchinocandinsB核作為更高級化學修飾的基礎，增加了技術複雜性和價值鏈價值。製藥公司越來越傾向於將這些資本密集的研發項目出售給擁有專業商業基礎設施的合作夥伴公司，以最大限度地提高市場滲透率。例如，Sidala Therapeutics在2024年8月發布的2024年第二季財報中宣布，預計在雷射芬淨的專利權持續時間內可節省約1.28億美元的成本。這是由於該公司將該資產策略性地出售給了Mundipharma進行全球商業化，並清楚地表明了整個行業將資源重新分配到高附加價值新一代療法的趨勢。

同時，關鍵專利的到期以及隨後大型無菌注射劑生產商的湧入，正推動阿尼芬淨原料藥非專利藥生產的快速擴張。這一趨勢使Echinocandins菌素類療法的可及性更加普及，迫使現有原料藥生產商最佳化發酵產量，以在滿足非專利核准所需的嚴格純度標準的同時，保持價格競爭力。該領域的快速成長有利於那些擁有垂直整合能力、能夠在價格壓力下維持利潤率的生產商。 2024年5月，Grand Pharma在「2024年第四季及全年財務業績報告」中宣布，其合併銷售額年增56%。這一成長主要得益於其核心無菌注射劑市場的強勁銷售成長，反映了全球對具成本效益非專利抗真菌製劑日益成長的需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：EchinocandinsB的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（粉末、液體）
    • 依應用領域（抗真菌藥物、藥物研發等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：EchinocandinsB北美市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：EchinocandinsB的歐洲市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區棘EchinocandinsB市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：EchinocandinsB在中東和非洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：EchinocandinsB在南美的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球EchinocandinsB市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Glenmark Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Mylan NV
  • Fresenius SE & Co. KGaA
  • Merck & Co., Inc.
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Cidara Therapeutics, Inc.
  • Hikma Pharmaceuticals PLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27599

The Global Echinocandin B Market is projected to expand from USD 47.58 Billion in 2025 to USD 65.75 Billion by 2031, achieving a compound annual growth rate of 5.54%. Serving as a critical lipopeptide intermediate typically obtained through the fermentation of Aspergillus species, Echinocandin B is essential for synthesizing the echinocandin class of antifungal agents, such as anidulafungin. The market is driven primarily by the rising global incidence of invasive fungal infections and the urgent need for effective treatments against azole-resistant pathogens in immunocompromised patients. This demand is supported by the growing disease burden; the Global Action Fund for Fungal Infections estimated in 2024 that approximately 6.55 million people worldwide are affected annually by life-threatening fungal diseases, creating a direct requirement for these essential drug precursors.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 47.58 Billion
Market Size 2031USD 65.75 Billion
CAGR 2026-20315.54%
Fastest Growing SegmentDrug Development
Largest MarketNorth America

Despite strong demand, the market encounters a significant obstacle due to the high cost of therapy associated with echinocandin-based drugs relative to conventional azoles. The intricate fermentation and semi-synthetic manufacturing processes needed to produce the Echinocandin B nucleus lead to elevated production costs, which are inevitably reflected in the final pricing. This financial barrier hinders the widespread adoption of these therapeutics in price-sensitive developing regions with limited healthcare budgets, thereby constraining the overall potential for market expansion.

Market Driver

The increasing prevalence of multidrug-resistant fungal pathogens is the primary force accelerating the Global Echinocandin B Market. As immunocompromised patient populations grow due to rising rates of organ transplants and oncological therapies, susceptibility to severe mycoses has intensified, necessitating robust supply chains for echinocandin intermediates. This urgency is highlighted by the rapid spread of pathogens such as Candida auris, which often displays resistance to traditional azole therapies, thus prioritizing echinocandin-class drugs as a first-line defense. According to the December 2024 'Tracking C. auris' surveillance report by the Centers for Disease Control and Prevention, clinical cases of this multidrug-resistant fungus in the U.S. reached 4,514 in 2023, indicating a continued upward trend that directly increases manufacturing requirements for effective lipopeptide-based antifungals.

Simultaneously, the expansion of pharmaceutical R&D for new antifungal formulations is reshaping market dynamics by driving demand for high-purity Echinocandin B nuclei. Pharmaceutical developers are actively commercializing next-generation echinocandins with enhanced stability and dosing schedules, a process heavily reliant on advanced semi-synthetic manufacturing. In May 2024, Cidara Therapeutics reported in its 'First Quarter 2024 Financial Results' that it received a milestone payment of approximately $11.1 million from Mundipharma following the European Union approval of the novel echinocandin rezafungin, confirming the commercial viability of these advanced therapies. Further reflecting confidence in this therapeutic area, F2G secured a $100 million financing round in 2024 led by the AMR Action Fund to advance late-stage antifungal development, underscoring the significant global investment entering the sector.

Market Challenge

The high cost of therapy associated with echinocandin-based drugs presents a significant hurdle to market expansion, particularly in cost-sensitive developing regions. Producing the Echinocandin B nucleus involves complex fermentation and semi-synthetic processes that inherently increase manufacturing expenses. These elevated costs are transferred to the final pricing, establishing a substantial financial barrier for healthcare systems with restricted budgets. Consequently, medical providers in these areas often resort to conventional, lower-cost azoles despite the clinical benefits of echinocandins, thereby limiting the addressable market for these advanced therapeutics.

This price sensitivity is further exacerbated by the broader economic strain that fungal diseases place on healthcare infrastructure, forcing administrators to strictly manage pharmacy expenditures. According to the Infectious Diseases Society of America, the total annual economic burden of fungal diseases in the United States was estimated to be approximately $19.4 billion in 2024. Such immense financial pressure compels healthcare institutions to prioritize cost containment, further suppressing the adoption rates of premium echinocandin treatments in favor of more affordable alternatives, which directly hampers volume growth in the Global Echinocandin B Market.

Market Trends

The rise of next-generation long-acting derivatives is fundamentally altering the commercial landscape for echinocandin intermediates, shifting the market from daily formulations like anidulafungin toward weekly dosing regimens. This transition requires the Echinocandin B nucleus to serve as a scaffold for more advanced chemical modifications, thereby increasing the technical complexity and value of the supply chain. Pharmaceutical companies are increasingly divesting these capital-intensive development programs to partners with specialized commercial infrastructure to maximize market penetration. For instance, Cidara Therapeutics projected in its 'Second Quarter 2024 Financial Results' in August 2024 that it would achieve approximately $128 million in cost savings over the patent life of rezafungin following the strategic divestiture of the asset to Mundipharma for global commercialization, illustrating the industry-wide push to realign resources toward these high-value, next-generation therapies.

At the same time, the market is experiencing a rapid expansion of generic anidulafungin API production, driven by the expiration of key patents and the subsequent entry of large-scale sterile injectable manufacturers. This trend is democratizing access to echinocandin therapies, forcing incumbent API producers to optimize fermentation yields to compete on price while meeting the stringent purity standards required for generic regulatory approvals. The intense volume growth in this segment benefits manufacturers with vertically integrated capabilities who can sustain margins despite pricing pressures. In May 2024, Gland Pharma reported a 56% year-over-year increase in consolidated revenue in its 'Financial Results for the Fourth Quarter and Full Year ended March 31, 2024', a surge attributed to robust volume growth in its core sterile injectable markets, validating the accelerating global demand for cost-effective generic antifungal formulations.

Key Market Players

  • Glenmark Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Fresenius SE & Co. KGaA
  • Merck & Co., Inc.
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Cidara Therapeutics, Inc.
  • Hikma Pharmaceuticals PLC

Report Scope

In this report, the Global Echinocandin B Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Echinocandin B Market, By Type

  • Powder
  • Liquid

Echinocandin B Market, By Application

  • Antifungal Drugs
  • Drug Development
  • Others

Echinocandin B Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Echinocandin B Market.

Available Customizations:

Global Echinocandin B Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Echinocandin B Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Powder, Liquid)
    • 5.2.2. By Application (Antifungal Drugs, Drug Development, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Echinocandin B Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Echinocandin B Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Echinocandin B Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Echinocandin B Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Echinocandin B Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Echinocandin B Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Echinocandin B Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Echinocandin B Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Echinocandin B Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Echinocandin B Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Echinocandin B Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Echinocandin B Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Echinocandin B Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Echinocandin B Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Echinocandin B Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Echinocandin B Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Echinocandin B Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Echinocandin B Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Echinocandin B Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Echinocandin B Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Echinocandin B Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Echinocandin B Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Echinocandin B Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Echinocandin B Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Echinocandin B Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Glenmark Pharmaceuticals Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Teva Pharmaceutical Industries Ltd.
  • 15.3. Sun Pharmaceutical Industries Ltd.
  • 15.4. Mylan N.V.
  • 15.5. Fresenius SE & Co. KGaA
  • 15.6. Merck & Co., Inc.
  • 15.7. Astellas Pharma Inc.
  • 15.8. Pfizer Inc.
  • 15.9. Cidara Therapeutics, Inc.
  • 15.10. Hikma Pharmaceuticals PLC

16. Strategic Recommendations

17. About Us & Disclaimer